Chemical composition of hepatic lipids mediates reperfusion injury of the macrosteatotic mouse liver through thromboxane A(2)

J Hepatol. 2011 Dec;55(6):1291-9. doi: 10.1016/j.jhep.2011.04.019. Epub 2011 May 19.

Abstract

Background & aims: Chemical composition of hepatic lipids is an evolving player in steatotic liver ischemia/reperfusion (I/R) injury. Thromboxane A(2) (TXA(2)) is a vasoactive pro-inflammatory lipid mediator derived from arachidonic acid (AA), an omega-6 fatty acid (Ω-6 FA). Reduced tolerance of the macrosteatotic liver to I/R may be related to increased TXA(2) synthesis due to the predominance of Ω-6 FAs.

Methods: TXA(2) levels elicited by I/R in ob/ob and wild type mice were assessed by ELISA. Ob/ob mice were fed Ω-3 FAs enriched diet to reduce hepatic synthesis of AA and TXA(2) or treated with selective TXA(2) receptor blocker before I/R.

Results: I/R triggered significantly higher hepatic TXA(2) production in ob/ob than wild type animals. Compared with ob/ob mice on regular diet, Ω-3 FAs supplementation markedly reduced hepatic AA levels before ischemia and consistently blunted hepatic TXA(2) synthesis after reperfusion. Sinusoidal perfusion and hepatocellular damage were significantly ameliorated despite downregulation of heme oxygenase-1. Hepatic transcript and protein levels of IL-1β and neutrophil recruitment were significantly diminished after reperfusion. Moreover, TXA(2) receptor blockage conferred similar protection without modification of the histological pattern of steatosis. A stronger protection was achieved in the steatotic compared with lean animals.

Conclusions: Enhanced I/R injury in the macrosteatotic liver is explained, at least partially, by TXA(2) mediated microcirculatory failure rather than size-related mechanical compression of the sinusoids by lipid droplets. TXA(2) blockage may be a simple strategy to include steatotic organs and overcome the shortage of donor organs for liver transplantation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 6-Ketoprostaglandin F1 alpha / biosynthesis
  • Animals
  • Arachidonic Acid / metabolism
  • Fatty Acids, Omega-3 / administration & dosage
  • Fatty Liver / complications
  • Fatty Liver / metabolism*
  • Fatty Liver / pathology
  • Lipid Metabolism
  • Lipids / chemistry*
  • Liver / blood supply
  • Liver / drug effects
  • Liver / injuries*
  • Liver / metabolism*
  • Macrophage Activation / drug effects
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Obese
  • Microcirculation / drug effects
  • Neutrophil Activation / drug effects
  • Oxidative Stress / drug effects
  • Receptors, Thromboxane A2, Prostaglandin H2 / antagonists & inhibitors
  • Reperfusion Injury / etiology*
  • Reperfusion Injury / metabolism*
  • Reperfusion Injury / pathology
  • Thromboxane A2 / metabolism*

Substances

  • Fatty Acids, Omega-3
  • Lipids
  • Receptors, Thromboxane A2, Prostaglandin H2
  • Arachidonic Acid
  • Thromboxane A2
  • 6-Ketoprostaglandin F1 alpha